Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.

Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM.

J Diabetes Complications. 1998 Jul-Aug;12(4):181-6.

PMID:
9647334
3.

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

Kato K, Yamada D, Midorikawa S, Sato W, Watanabe T.

Metabolism. 2000 May;49(5):662-5.

PMID:
10831180
4.

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.

Ann Intern Med. 1998 Feb 1;128(3):176-85.

PMID:
9454525
5.

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.

Clin Pharmacol Ther. 1997 Aug;62(2):194-202.

PMID:
9284856
6.
7.

Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.

Kumar S, Prange A, Schulze J, Lettis S, Barnett AH.

Diabet Med. 1998 Sep;15(9):772-9.

PMID:
9737807
8.

Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus.

Kuzuya T, Kosaka K, Akanuma Y, Shigeta Y, Kaneko T.

Diabetes Res Clin Pract. 1998 Aug;41(2):121-9.

PMID:
9789718
9.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
11.

The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.

Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES, Veves A.

Metabolism. 2003 Feb;52(2):173-80.

PMID:
12601628
12.
13.

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW.

Diabetes Care. 1998 Sep;21(9):1455-61.

PMID:
9727891
14.

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW.

Diabetes. 1997 Mar;46(3):433-9.

PMID:
9032099
15.

Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.

Maruyama S, Yanagisawa K, Kanamuro R, Teno S, Iwamoto Y.

Diabetes Res Clin Pract. 2001 Sep;53(3):161-4.

PMID:
11483231
16.
17.

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J.

N Engl J Med. 1994 Nov 3;331(18):1188-93.

18.

Troglitazone: an antidiabetic agent.

Chen C.

Am J Health Syst Pharm. 1998 May 1;55(9):905-25. Review.

PMID:
9588250
19.

Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.

Gómez-Pérez FJ, Aguilar-Salinas CA, Vázquez-Chávez C, Fanghänel-Salmón G, Gallegos-Martínez J, Gómez-Diaz RA, Salinas-Orozco S, Chavira-López IJ, Sánchez-Reyes L, Torres-Acosta EM, Tamez R, López A, Guillén LE, Cesarman G.

Metabolism. 2002 Jan;51(1):44-51.

PMID:
11782871
20.

Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.

Yatagai T, Nakamura T, Nagasaka S, Kusaka I, Ishikawa SE, Yoshitaka A, Ishibashi S.

Diabetes Res Clin Pract. 2004 Jan;63(1):19-26.

PMID:
14693409

Supplemental Content

Support Center